Antibody Drug Conjugate Drug Industry 2018 Global Pipeline Review and Outlook 2023

Apr 5, 2018

WiseGuyReports.Com Publish a New Market Research Report On –“ Antibody Drug Conjugate Drug Industry 2018 Global Pipeline Review and Outlook 2023”.

Pune, India - April 5, 2018 /MarketersMedia/ —

Description:

Antibody Drug Conjugates are the fastest growing class of oncology therapeutics. These are monoclonal antibody based therapies which have achieved great success in the field of cancer treatment, primarily when used with cytotoxic drugs. ADC is a class of therapeutics which harnesses the antigen-selectivity of monoclonal antibodies to deliver the highly potent cytotoxic drugs to antigen expressing tumor cells. The use of monoclonal antibody directed delivery confers a therapeutic index to highly potent cytotoxic drugs, increasing both the efficacy and safety of therapy. Such novel anti-cancer drugs are being used these days to target cancers, while minimizing the exposure of healthy tissue. The recent approval of four ADCs in the global market and a strong pipeline of such drugs, highlight the potential for new therapeutic innovations in this industry.

Get a Sample Report @ https://www.wiseguyreports.com/sample-request/3102977-global-antibody-drug-conjugate-drug-sales-pipeline-analysis

For more information or any query mail at [email protected]

According to the report entitled “Global Antibody Drug Conjugate Drug Sales, Pipeline Analysis (By Phase, Linker, Technology, and Indication) & Market Forecast to 2023”, the Global Antibody Drug Conjugates Market is anticipated to witness a double digit growth during 2017-2023. The report provides information about the current and future market scenario of the Global ADCs Market. The report also highlights the major drivers, such as increasing incidences of cancer and advances in linking technologies, for the Global Antibody Drug Conjugates Market. Furthermore, the report also gives information related to the commercially available ADCs such as ADCETRIS, Kadcyla, Mylotarg and Besponsa.

Moreover, few hindrances, such as high cost of production cost, lack of experienced manufacturers and regulatory challenges, which are slowing down the growth of the Global ADCs Market, have also been mentioned in the report. In addition, the report also highlights various trends and developments taking place in this market.

Furthermore, in this report, we have structured the information regarding ADCs at various stages of clinical development that are under research or in collaboration, and those individually being developed by companies. The pipeline chapter provides in depth analysis of ADCs of companies as well as research organizations by clinical phase, indications for which they are being developed, type of linker, drugs, and technology. Additionally, the study provides all-inclusive current analysis of various ADCs in advanced as well as early stages of development. Moreover, our report places an emphasis on the strategic alliances that can impact industry’s growth.

The prominent players in Global Antibody Drug Conjugates Market have been discussed in the last section of the report. A brief business overview and financial information about each of these players has been provided, along with their product portfolios, product pipeline and recent developments. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the Global Antibody Drug Conjugates Market.

Complete Report Details @ https://www.wiseguyreports.com/reports/3102977-global-antibody-drug-conjugate-drug-sales-pipeline-analysis

Table Of Contents – Major Key Points

1. Analyst View

2. Research Methodology

3. Antibody Drug Conjugate (ADC) - An Introduction

4. Global Antibody Drug Conjugates Market Outlook to 2023

5. Commercialized Antibody Drug Conjugates
5.1 ADCETRIS
5.2 Kadcyla
5.3 Mylotarg
5.4 Besponsa

6. Antibody Drug Conjugates Pipeline Analysis
6.1 By Companies
6.1.1 By Clinical Phase
6.1.2 By Indication
6.1.3 By Drug
6.1.4 By Type of Linker
6.1.5 By Technology
6.2 By Research Organizations
6.2.1 By Phase
6.2.2 By Indication
6.2.3 By Drug
6.2.4 By Type of Linker
6.2.5 By Technology

7. Drivers and Challenges
7.1 Drivers
7.1.1 Rising Global Cancer Epidemics
7.1.2 Advances in Linking Technologies Re-Instills Hope in ADC
7.1.3 Efforts towards Patent Protection to Drive ADC Market
7.1.4 Increasing Demand for Antibody Drug Conjugates
7.2 Challenges
7.2.1 Production Hurdles and Cost
7.2.2 Inadequacy of Experienced Manufacturers
7.2.3 Regulatory Challenges

8. Major Potential Antibody Drug Conjugates in Pipeline
8.1 By Companies
8.1.1 Glembatumumab Vedotin Therapeutics/CDX-011 - Celldex
8.1.2 Coltuximab Ravtansine/SAR3419 - ImmunoGen Inc.
8.1.3 Indatuximab Ravtansine/BT-062 – Biotest AG
8.1.4 Anti-PSMA ADC Therapeutic - Progenics Pharmaceuticals
8.1.5 Polatuzumab Vedotin/RG7596 - F. Hoffman-La Roche Ltd.
8.1.6 DMUC-4064A/RG7882 - F. Hoffman-La Roche Ltd.
8.1.7 Mirvetuximab Soravtansine/IMGN853 - ImmunoGen Inc.
8.2 By Research Organizations
8.2.1 SGM-101 - SurgiMab in Collaboration with Center for Human Drug Research, Netherlands
8.2.2 MOC31-PE - Creative Biolabs in Collaboration with Oslo University Hospital

9. Trends and Developments
9.1 ADC at the Forefront of Treating Hematological Malignancies
9.2 ADCs Proving Advantageous for Breast Cancer Patients

10. Strategic Alliances in the Global Antibody Drug Conjugates Industry

Continue……

For more information or any query mail at [email protected]

ABOUT US:
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.

Contact Info:
Name: Norah Trent
Email: [email protected]
Organization: WiseGuy Research Consultants Pvt Ltd.
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028
Phone: +1-646-845-9349

Source URL: https://marketersmedia.com/antibody-drug-conjugate-drug-industry-2018-global-pipeline-review-and-outlook-2023/325507

For more information, please visit https://www.wiseguyreports.com

Source: MarketersMedia

Release ID: 325507

WNBA offseason begins with search for first commissioner

UNCASVILLE, Connecticut — With Golden State the newly crowned WNBA champion, the league turns its attention to a pivotal offseason. Unlike last year when a new collective bargaining agreement dominated the offseason, the top priority is finding new leadership. Outgoing Commissioner Cathy Engelbert, who has been in the position nearly seven years, announced last month that she was retiring at the end of the calendar with year. A search has begun and the next commissiner will inherit a host of issues, including officiating, the transgender debate scheduling and improving a strained relationship with players. Here's a look at some of the main topics that will be center stage over the next few months before the season tips off again next May with a 50-game schedule: Improving relationship with players The league thrived in many ways during Engelbert's tenure. Under her leadership, the WNBA enjoyed record growth and popularity, and signed a record-breaking broadcasting deal. Players surpassed million-dollar annual salaries. But despite her accomplishments, Engelbert's relationship with players cordial at best, confrontational at other times. Breanna Stewart may have summed it up best when said that players “respect” Engelbert. Building a stronger relationship with players will likely be one of the first things on the new commissioner's to-do list. Officiating improvements Complaints about officiating felt like it reached a crescendo this season. The WNBA is taking various steps to address the situation. The league is opening a the new officiating replay center. The WNBA, along with the NBA, completed a multi-million dollar renovation in New Jersey to the official replay center. It will be fully operational next season. The WNBA is working to upgrade techonology and video infrastructure at arenas to help the process. There were improvements this year after a rough start to the season where teams struggled to adjust to the emphasis on players' freedom of movement. The league put together a task force, which Minnesota coach Cheryl Reeve is on, in the offseason to help clean up some of the physicality in the game. The main point of emphasis was to help players’ freedom of movement. Despite some hiccups early on, it has led to more offense as teams are averaging around 86 points a game — the highest ever. Scheduling challenges WNBA teams will play a record 50 games next season. It helps that there's no break for either the women's FIBA World Cup or the Olympics. Still the playoffs could once again go into the start of the NBA season. Nearly every team will be playing in an NBA arena next season with a few exceptions. To avoid a repeat of this year where Game 6 of the WNBA Finals was played at 12:30 p.m. EDT because of arena availability, the teams need to lock in potential playoff dates way ahead of time. Transgender debate The WNBA has criticized those trying to create a narrative about transgender women playing in the league. “There are no immediate eligibility matters affecting the WNBA, and we strongly denounce the bad-faith efforts to use these topics to demean or marginalize others,” a league spokesperson said in August after an anti-hate task force met virtually and discussed a variety of topics, including social media vitriol and transgender athletes. The league’s collective bargaining agreement states that “only players who are women are eligible to play in the WNBA,” but it does not include any more specific language about gender identity or sex assigned at birth. Two former NBA players, Enes Kanter Freedom and Royce White, declared themselves eligible for the WNBA draft, saying they identify as women. The league has said they aren't eligible. Welcome back Houston Comets The Connecticut Sun will relocate to Houston as the Comets will return after folding in 2008. The Sun were bought by the Houston Rockets ownership group led by Tilman Fertitta for $300 million. The Comets will begin play next season and are tied with Toronto for the best chance to win the WNBA draft lottery that will be held on Nov. 15. While the Sun relocated to Houston, there will be no expansion teams entering the league next year. Cleveland will enter in 2028, Detroit in 2029 and Philadelphia in 2030.